TABLE OF CONTENTS
Large caps have dominated stock market performance in recent years, but that trend is bound to change.
Getty Images
The rest of 2025 promises some surprises for investors. Interest rates may dip, inflation may rise and big tech’s momentum may slow. At the same time, high-growth midcap stocks may finally find their place in the limelight. Let’s look at five stocks worthy of further research as potential candidates for your portfolio this month.
5 Stocks To Buy In September 2025
The five top stocks for September have optimistic outlooks, positive cash flow and manageable debt levels. Specifically, they meet these screening criteria:
- Expected EPS growth this year over 25%. Higher profits drive higher stock prices.
- Price target upside above 35%. Analysts expect these stocks to be worth more in the next 12 months.
- Positive free cash flow. Positive free cash flow means the company generates more than enough cash to run the business and maintain its capital assets.
- Debt/free cash flow ratio under 2. The debt/free cash flow ratio indicates how many years the company would take to pay off its debt with free cash flow. Lower is better.
- Positive analyst ratings. Experts say these stocks are poised for growth.
The table below identifies the five stocks for September, ordered from largest market capitalization to smallest.
Let’s take a closer look at each stock, with metrics sourced from company reports and stockanalysis.com.
For more investing ideas, see best stocks for 2025.
Monday.com Ltd. by the numbers:
MORE FOR YOU
- Stock price: $193
- 2024 EPS: $0.62
- Expected EPS growth this year: 550.4%
- Price target upside: 60.7%
- Annual free cash flow: $298 billion
- Debt/free cash flow ratio: 0.39
Monday.com Business Overview
Monday.com provides customizable project management and automation software. The application suite is sold on a subscription basis to more than 240,000 business customers.
Why MNDY Stock Is A Top Choice
At least nine analysts rate Monday.com a strong buy, and the average price target is $310.17. The consensus 2025 EPS expectation is $4.03, up from $0.62 in 2024.
Monday.com fills a niche between complicated enterprise software and off-the-shelf programs that are too rigid to be functional. That niche has proven to be popular. The company operates in 200 countries and is gaining traction with high-value enterprise customers. The number of customers producing annual recurring revenue (ARR) of at least $100,000 is up 46% over the past year. The number of customers producing at least $50,000 ARR is up 36%.
The business momentum extends beyond the past 12 months. In 2020, Monday.com’s revenue was $161 million—the same metric reached $972 million in 2024. The strong revenue growth created operating leverage, which enabled positive non-GAAP operating income in 2023 and 2024.
Wix.com Ltd. by the numbers:
- Stock price: $141.08
- 2024 EPS: $2.36
- Expected EPS growth this year: 193.1%
- Price target upside: 52.3%
- Annual free cash flow: $480 billion
- Debt/free cash flow ratio: 1.81
Wix.com Business Overview
Wix sells a website-creation platform on a subscription basis to more than 290 million users. The company also processes e-commerce payments, sells SEO and marketing tools, and shares revenue with partners that publish tools in its app marketplace.
Why WIX Stock Is A Top Choice
Eight analysts rate Wix.com a strong buy, and the average price target is $214.84. The consensus 2025 EPS target is $6.92, up from $2.36 in 2024.
Wix has generated consistent revenue growth in recent years, driven by increases in domain-hosting demand, transaction income and partner revenue-share. Free cash flow has grown from $32 million in 2022 to $488 million in 2024.
Wix additionally purchased growth startup Base44 this year to expand its presence in vibe coding. Vibe coding involves developing software code by asking an AI program to produce it. Base44’s customer base includes website builders and application developers. When acquired, Base44 had just a few million dollars in ARR—but is now tracking toward $40 million to $50 million ARR by year-end.
3. Dolby Laboratories (DLB)
Dolby Laboratories by the numbers:
- Stock price: $71.68
- 2024 EPS: $2.69
- Expected EPS growth this year: 48.7%
- Price target upside: 42.7%
- Annual free cash flow: $297 billion
- Debt/free cash flow ratio: 0.09
Dolby Labs Business Overview
Dolby sells audio and visual technology and services to movie and TV studios, content creators and broadcasters.
Why DLB Stock Is A Top Choice
Two analysts rate Dolby Laboratories a strong buy, and the average price target is $102.25. The consensus fiscal 2025 EPS target is $4, up from $2.69 in fiscal 2024.
Dolby’s stock price has disappointed recently—despite producing double-digit EPS gains in fiscal years 2023 and 2024. On the company’s last earnings call, CFO and senior VP Robert Park cited uncertain macroeconomic conditions.
Even so, Dolby met its guidance in the quarter, partly thanks to new wins in the automotive end market and momentum with content creators, device manufacturers and content distributors. The company produced $68 million in operating cash flow in the quarter and had $777 million in cash and investments on its balance sheet as of June 27.
4. Krystal Biotech (KRYS)
Krystal Biotech by the numbers:
- Stock price: $147.70
- 2024 EPS: $3.00
- Expected EPS growth this year: 68.7%
- Price target upside: 38.7%
- Annual free cash flow: $119 billion
- Debt/free cash flow ratio: 0.05
Krystal Biotech Business Overview
Krystal Biotech is a commercial-stage biotech company that focuses on re-dosable genetic therapies. The company’s first commercial product is Vyjuvek, which treats dystrophic epidermolysis bullosa. DEB, as it’s known, causes delicate skin and chronic wounds.
Why KRYS Stock Is A Top Choice
Seven analysts rate Krystal Biotech a strong buy, and the average price target is $204.90. The consensus 2025 EPS target is $5.06, up from around $3 in 2024.
Krystal Biotech estimates the global market opportunity for Vyjuvek is more than $1 billion. The product launched in the U.S. in 2023 and in Germany in 2025. The expansion plan includes other European markets, Japan and the rest of the world. The company also has a related opportunity to address ocular complications of DEB, which currently has no FDA-approved therapy. Notably, Krystal Biotech owns two U.S. manufacturing facilities with the capacity to support Vyjuvek’s expansion.
While the company expands Vyjuvek, it’s also working on a robust therapy pipeline that addresses respiratory, oncology and ophthalmology conditions.
5. Harmony Biosicences Holdings (HRMY)
Harmony Biosciences by the numbers:
- Stock price: $36.89
- 2024 EPS: $2.51
- Expected EPS growth this year: 27.7%
- Price target upside: 50.0%
- Annual free cash flow: $219 billion
- Debt/free cash flow ratio: 0.67
Harmony Biosciences Business Overview
Harmony Biosciences is a commercial-stage pharmaceutical company that develops and sells therapies for rare neurological disorders. The company’s first commercial product is Wakix (pitolisant), which treats symptoms associated with narcolepsy.
Why HRMY Stock Is A Top Choice
Five analysts rate Harmony Biosciences a strong buy, and the average price target is $55.33. The consensus 2025 EPS expectation is $3.21, up from $2.51 in 2024.
Harmony’s flagship product Wakix continues to show momentum, producing $714.7 million in 2024 sales, a 20% annual gain. In February, President and CEO Jeffrey Dayno said 2025 would be a “transformational year” for Harmony and predicted Wakix would produce sales of $820 million to $860 million. In August, the company reported $385 million in year-to-date sales and reaffirmed the $820 million to $860 million guidance.
Harmony Biosciences is also developing additional formulations of pitolisant, as well as treatments for epilepsy and the genetic disorder Fragile X syndrome, or FXS. There is currently no approved treatment for FXS.
As of June 30, Harmony had $546 million in cash on its balance sheet.
Bottom Line
Large caps have dominated stock market performance in recent years, but that trend is bound to change. It’s tough to predict the timing of that transition—especially when the economic outlook is murky. The best you can do is keep investing in businesses with solid fundamentals and remain patient if stock prices turn turbulent.